Based in Newport Beach, California, CureDuchenne Ventures offers investments ranging from $50,000 to $5 million to support projects related to Duchenne muscular dystrophy. They also provide partnership and collaboration opportunities with the FDA, pharmaceutical, and biotechnology industry. Funding is available through grants, loans, or equity financing. CureDuchenne Ventures has invested in several companies and research projects focused on Duchenne muscular dystrophy, with the goal of driving significant investment from biotech and pharmaceutical companies and venture philanthropists. The firm was founded in 2003 by Paul and Debra Miller, who combine fundraising and venture philanthropy to support research and find effective treatments for the disease.